Open AccessLenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience
Author(s) -
Rakesh Sharma,
Palanki Satya Dattatreya,
Amritha Suresh,
Ch Mohana Vamsy
Publication year - 2021
Publication title -
journal of cancer and tumor international
Language(s) - English
Resource type - Journals
ISSN - 2454-7360
DOI - 10.9734/jcti/2021/v11i430156
Subject(s) - lenvatinib , medicine , refractory (planetary science) , anaplastic thyroid cancer , thyroid carcinoma , oncology , thyroid , carcinoma , thyroid cancer , physics , astrobiology
Anaplastic Thyroid Carcinoma (ATC) is an aggressive rare form of caner with limited treatment options and short survival. In view of initial case reports have shown some good clinical response with lenvatinib, we used the same in our institute. We are presenting a retrospective series of 4 cases between 2018-2021. It showed very promising results with 75% showing clinically meaningful regression of tumor. Hypertension is the most common side effect, which should be aggressively managed. We feel that, lenvatinib remains a safe and effective option to explore in patients with refractory anaplastic thyroid carcinoma.